Unoprostone

Unoprostone

SCHEMBL194651

CCCCCCCC(=O)CC[C@@H]1[C@@H](C/C=C\CCCC(=O)O)[C@@H](O)C[C@H]1O

nearest known ligand 0.73

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PGR P06401 2/20 0.73
ADORA3 P0DMS8 2/20 0.73
SLC6A2 P23975 2/20 0.73
ADRA2C P18825 1/20 0.73
HTR2B P41595 1/20 0.73
MC3R P41968 1/20 0.73
SLC6A3 Q01959 1/20 0.73
PDE4D Q08499 1/20 0.73
SCN5A Q14524 1/20 0.73
TBXA2R P21731 4/20 0.57
PTGFR P43088 3/20 0.57
LMNA P02545 3/20 0.57
ALDH1A1 P00352 2/20 0.57
PTGER1 P34995 2/20 0.57
PTGER3 P43115 2/20 0.57
SLCO2A1 Q92959 2/20 0.57
PTGER4 P35408 1/20 0.57
PTGDR Q13258 1/20 0.57
KMT2A Q03164 2/20 0.52
MEN1 O00255 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Unoprostone SCHEMBL18605546 1.00 PGR (0.73) PGRADORA3SLC6A2ADRA2CHTR2B
Unoprostone SCHEMBL1286326 1.00 PGR (0.73) PGRADORA3SLC6A2ADRA2CHTR2B
Unoprostone SCHEMBL14957866 1.00 PGR (0.73) PGRADORA3SLC6A2ADRA2CHTR2B
Unoprostone SCHEMBL2469324 1.00 PGR (0.73) PGRADORA3SLC6A2ADRA2CHTR2B
SCHEMBL6409055 1.00 PGR (0.73) PGRADORA3SLC6A2ADRA2CHTR2B
Unoprostone SCHEMBL2469329 1.00 PGR (0.73) PGRADORA3SLC6A2ADRA2CHTR2B
Unoprostone SCHEMBL1286324 1.00 PGR (0.73) PGRADORA3SLC6A2ADRA2CHTR2B
SCHEMBL6409062 1.00 PGR (0.73) PGRADORA3SLC6A2ADRA2CHTR2B
Unoprostone SCHEMBL22965277 1.00 PGR (0.73) PGRADORA3SLC6A2ADRA2CHTR2B
Unoprostone SCHEMBL572177 1.00 PGR (0.73) PGRADORA3SLC6A2ADRA2CHTR2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 4200 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4727651-A1 METHOD OF ENHANCING THE SYSTEMIC HYPOGLYCEMIC EFFECT OF TOPICALLY APPLIED INSULIN WITH THE USE OF PROSTAGLANDIN ANALOGUES: A NOVEL FIXED COMBINATION EYE DROP FORMULATION OF INSULIN AND PROSTAGLANDIN ANALOGUE FOR THE LOWERING OF BLOOD GLUCOSE LEVEL Gosiengfiao, David Harold (PH) 2026-04-22 EP claimed
EP-4724079-A2 METHODS AND COMPOSITIONS FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION Stealth BioTherapeutics Inc. (US) 2026-04-15 EP claimed
US-12589025-B2 Intraocular devices, systems, and methods SIGHT SCIENCES, INC. (US) 2026-03-31 US claimed
US-20260083822-A1 Topical Ocular Insulin Delivery Enhanced by Prostaglandin Analogues GOSIENGFIAO DAVID HAROLD (PH) 2026-03-26 US claimed
US-20260048096-A1 METHODS AND COMPOSITIONS FOR PRESERVING THE RETINAL OUTER NUCLEAR LAYER (ONL), PHOTORECEPTORS, AND RETINAL THICKNESS STEALTH BIOTHERAPEUTICS INC. (US) 2026-02-19 US claimed
US-12551525-B2 Collagen peptide-based medicament compositions and devices and methods of production and use thereof SUSTAIN HOLDINGS, LLC (US) 2026-02-17 US claimed
US-20260034056-A1 PHARMACEUTICAL COMPOSITIONS FOR TREATING OCULAR DISEASES OR DISORDERS ALCON INC (CH) 2026-02-05 US claimed
US-20260027105-A1 COMPOUND MEDICINE COMPOSITION FOR TREATING GLAUCOMA AND USE OF SAME SHENYANG PHARMACEUTICAL UNIVERSITY (CN) 2026-01-29 US claimed
US-20260000537-A1 CONTROLLED DRUG DELIVERY OCULAR IMPLANTS AND METHODS OF USING SAME GLAUKOS CORP (US) 2026-01-01 US claimed
EP-4626373-A2 BIO-ERODIBLE OCULAR IMPLANTS FOR TREATMENT OF CONDITIONS OF THE EYE Sight Sciences, Inc. (US) 2025-10-08 EP claimed
CN-1255064-A Use of 'alpha'-methyl-P-tyrosine to inhibit melanin production in iris melanocytes PHARMACIA & UPJOHN (SE) 2000-05-31 CN claimed
EP-0998277-A1 OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION Merck & Co., Inc. (a New Jersey corp.) (US) 2000-05-10 EP claimed
WO-2000022909-A2 SYSTEMS FOR ORAL DELIVERY BIOTECH AUSTRALIA PTY. LIMITED (AU) 2000-04-27 WO claimed
EP-0989972-A1 PROSTAGLANDIN PHARMACEUTICAL COMPOSITIONS NICOX S.A. (FR) 2000-04-05 EP claimed
EP-0977575-A1 THE USE OF $g(a)-METHYL-P-TYROSINE TO INHIBIT MELANIN PRODUCTION IN IRIS MELANOCYTES Pharmacia & Upjohn AB (SE) 2000-02-09 EP claimed
WO-2000004898-A1 OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION MERCK & CO., INC. (US) 2000-02-03 WO claimed
WO-1998058910-A1 PROSTAGLANDIN PHARMACEUTICAL COMPOSITIONS NICOX S.A. (FR) 1998-12-30 WO claimed
WO-1998053809-A1 OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION MERCK & CO., INC. (US) 1998-12-03 WO claimed
WO-1998047515-A1 THE USE OF α-METHYL-P-TYROSINE TO INHIBIT MELANIN PRODUCTION IN IRIS MELANOCYTES PHARMACIA & UPJOHN AB (SE) 1998-10-29 WO claimed
WO-1998022114-A1 A METHOD FOR PROMOTING TISSUE REPAIR DUMEX-ALPHARMA A/S (DK) 1998-05-28 WO claimed